Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilaria Mosca

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Epilepsia|May 19, 2023
A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetinePaolo Ambrosino, Francesca Ragona, Ilaria Mosca, et al.
Molecular Neurobiology|February 1, 2018
Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP<sub>2</sub>-Dependent K<sup>+</sup> Channel GatingPaolo Ambrosino, Elena Freri, Barbara Castellotti, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2022
Gain of function due to increased opening probability by two <i>KCNQ5</i> pore variants causing developmental and epileptic encephalopathyMario Nappi, Vincenzo Barrese, Lidia Carotenuto, et al.
Pharmacological Research|September 17, 2020
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathyMaria Virginia Soldovieri, Elena Freri, Paolo Ambrosino, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 17, 2018
Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized TherapyRobertino Dilena, Jacopo C DiFrancesco, Maria Virginia Soldovieri, et al.
Journal of Medicinal Chemistry|June 26, 2018
Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic ActivityAlessia Bertamino, Nunzio Iraci, Carmine Ostacolo, et al.
Journal of Medicinal Chemistry|May 23, 2024
<i>In Silico</i> Assisted Identification, Synthesis, and <i>In Vitro</i> Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 ChannelNunzio Iraci, Lidia Carotenuto, Tania Ciaglia, et al.
Cell Death & Disease|December 8, 2020
Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumorsAlessandro Alaimo, Marco Lorenzoni, Paolo Ambrosino, et al.
Annals of Neurology|April 16, 2023
KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological PropertiesMaria Cristina Cioclu, Ilaria Mosca, Paolo Ambrosino, et al.
Ebiomedicine|July 3, 2022
KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanismFrancesco Miceli, Charissa Millevert, Maria Virginia Soldovieri, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Epilepsia|May 19, 2023
A novel KCNC1 gain-of-function variant causing developmental and epileptic encephalopathy: "Precision medicine" approach with fluoxetinePaolo Ambrosino, Francesca Ragona, Ilaria Mosca, et al.
Molecular Neurobiology|February 1, 2018
Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP<sub>2</sub>-Dependent K<sup>+</sup> Channel GatingPaolo Ambrosino, Elena Freri, Barbara Castellotti, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 4, 2022
Gain of function due to increased opening probability by two <i>KCNQ5</i> pore variants causing developmental and epileptic encephalopathyMario Nappi, Vincenzo Barrese, Lidia Carotenuto, et al.
Pharmacological Research|September 17, 2020
Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathyMaria Virginia Soldovieri, Elena Freri, Paolo Ambrosino, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 17, 2018
Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized TherapyRobertino Dilena, Jacopo C DiFrancesco, Maria Virginia Soldovieri, et al.
Journal of Medicinal Chemistry|June 26, 2018
Identification of a Potent Tryptophan-Based TRPM8 Antagonist With in Vivo Analgesic ActivityAlessia Bertamino, Nunzio Iraci, Carmine Ostacolo, et al.
Journal of Medicinal Chemistry|May 23, 2024
<i>In Silico</i> Assisted Identification, Synthesis, and <i>In Vitro</i> Pharmacological Characterization of Potent and Selective Blockers of the Epilepsy-Associated KCNT1 ChannelNunzio Iraci, Lidia Carotenuto, Tania Ciaglia, et al.
Cell Death & Disease|December 8, 2020
Calcium cytotoxicity sensitizes prostate cancer cells to standard-of-care treatments for locally advanced tumorsAlessandro Alaimo, Marco Lorenzoni, Paolo Ambrosino, et al.
Annals of Neurology|April 16, 2023
KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological PropertiesMaria Cristina Cioclu, Ilaria Mosca, Paolo Ambrosino, et al.
Ebiomedicine|July 3, 2022
KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanismFrancesco Miceli, Charissa Millevert, Maria Virginia Soldovieri, et al.
Pageof 4